# ![@BIOTECHSCANNER Avatar](https://lunarcrush.com/gi/w:26/cr:twitter::1408278003109466115.png) @BIOTECHSCANNER BIOTECH SCANNER

BIOTECH SCANNER posts on X about $iova, $aqst, company, $arqt the most. They currently have [-----] followers and [---] posts still getting attention that total [-----] engagements in the last [--] hours.

### Engagements: [-----] [#](/creator/twitter::1408278003109466115/interactions)
![Engagements Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::1408278003109466115/c:line/m:interactions.svg)

- [--] Week [---------] +8,323%
- [--] Month [---------] +1,752%
- [--] Months [---------] +491%
- [--] Year [---------] +31%

### Mentions: [--] [#](/creator/twitter::1408278003109466115/posts_active)
![Mentions Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::1408278003109466115/c:line/m:posts_active.svg)

- [--] Week [--] -3.50%
- [--] Month [---] +5.80%
- [--] Months [---] +122%
- [--] Year [-----] -1.30%

### Followers: [-----] [#](/creator/twitter::1408278003109466115/followers)
![Followers Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::1408278003109466115/c:line/m:followers.svg)

- [--] Week [-----] +0.18%
- [--] Month [-----] +1.40%
- [--] Months [-----] +8.70%
- [--] Year [-----] +12%

### CreatorRank: [-------] [#](/creator/twitter::1408278003109466115/influencer_rank)
![CreatorRank Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::1408278003109466115/c:line/m:influencer_rank.svg)

### Social Influence

**Social category influence**
[stocks](/list/stocks)  30.91% [finance](/list/finance)  20% [countries](/list/countries)  2.73% [currencies](/list/currencies)  1.82% [technology brands](/list/technology-brands)  1.82% [cryptocurrencies](/list/cryptocurrencies)  1.82% [financial services](/list/financial-services)  1.82% [social networks](/list/social-networks)  0.91% [exchanges](/list/exchanges)  0.91% [automotive brands](/list/automotive-brands)  0.91%

**Social topic influence**
[$iova](/topic/$iova) #2, [$aqst](/topic/$aqst) #3, [company](/topic/company) #2543, [$arqt](/topic/$arqt) #3, [real world](/topic/real-world) 6.36%, [$fro](/topic/$fro) 6.36%, [in the](/topic/in-the) 5.45%, [$spry](/topic/$spry) 5.45%, [if you](/topic/if-you) 4.55%, [debt](/topic/debt) 4.55%

**Top accounts mentioned or mentioned by**
[@dancingtapas](/creator/undefined) [@dansfera](/creator/undefined) [@henry431171040](/creator/undefined) [@bailey13148](/creator/undefined) [@janvdes](/creator/undefined) [@mikedebreda](/creator/undefined) [@pistolonfire44](/creator/undefined) [@mucosalmelanoma](/creator/undefined) [@arthritisfinger](/creator/undefined) [@rickwhe78169487](/creator/undefined) [@nouvisalsok](/creator/undefined) [@canarymktintel](/creator/undefined) [@alexanderjgallo](/creator/undefined) [@yss4318](/creator/undefined) [@croupiercasino](/creator/undefined) [@cricket99238](/creator/undefined) [@markwhittier1](/creator/undefined) [@drmakaryfda](/creator/undefined) [@savallsicart](/creator/undefined) [@firetruck5](/creator/undefined)

**Top assets mentioned**
[Iovance Biotherapeutics, Inc. Common Stock (IOVA)](/topic/$iova) [Arcutis Biotherapeutics, Inc. (ARQT)](/topic/$arqt) [Frontline Ltd. (FRO)](/topic/$fro) [ARS Pharmaceuticals, Inc. (SPRY)](/topic/$spry) [Calliditas Therapeutics AB (CALT)](/topic/$calt) [AstraZeneca PLC (AZN)](/topic/$azn) [McKesson Corporation (MCK)](/topic/mckesson) [Viatris Inc (VTRS)](/topic/$vtrs) [GSK plc (GSK)](/topic/$gsk) [Sanofi (SNY)](/topic/sanofi) [Synthetify (SNY)](/topic/$sny) [State Street Corp (STT)](/topic/state-street-corp)
### Top Social Posts
Top posts by engagements in the last [--] hours

"$AQST - Part [--] of my predictions series. [--] day before FDA decision on $CALT Tarpeyo for CKD (chronic kidney disease) in a certain type of patient. I am currently educating healthcare professionals on how to test diagnose and treat CKD. Do you think this was handy when I researched this ticker As always I provided EVIDENCE. Result https://twitter.com/i/web/status/1767903309694660727 https://twitter.com/i/web/status/1767903309694660727"  
[X Link](https://x.com/BIOTECHSCANNER/status/1767903309694660727)  2024-03-13T13:19Z [----] followers, [----] engagements


"$ARQT - I am so happy for shareholders. This has turned out to be one of the biggest calls that I made. I predicted in May of [----] [--] months before Zoryve foam was approved for atopic dermatitis on July [--] [----]. The share price was about $7.80 in May of [----] and today its $31.20. Zoryve approval is part of my 6-0 PDUFA record. Why was I so confident that Zoryve would be approved BECAUSE I HAVE WORKED WITH THE DRUG BEFORE. ZORYVE (roflumilast) belongs to the phosphodiesterase4 (PDE4) inhibitor class of drugs. Before being used to treat psoriasis roflumilast was used to treat COPD exacerbations"  
[X Link](https://x.com/BIOTECHSCANNER/status/1997713873961357711)  2025-12-07T17:04Z [----] followers, [----] engagements


"$AQST - $VTRS Viatris $GSK Glaxo Smith Kline and $AZN AstraZeneca $SNY Sanofi have massive footprints in the allergy and immunology space. These are the companies that could partner with $AQST or buy it outright. The advantage of partnering with one of these companies is that AQST doesnt have to find another partner for other markets around the world. They are already there AQST [---] the topic epinephrine gel for Alopecia Areata (AA) would look very attractive as an asset to these companies. I have said it before that AQST [---] could turn out to be even bigger than Anaphylm. The Adrenaverse"  
[X Link](https://x.com/BIOTECHSCANNER/status/1998177368192467123)  2025-12-08T23:46Z [----] followers, [----] engagements


"$IOVA - [--] new analyst ratings just arrived. $9 from HC Wainwright and $14 from Wells Fargo. Yes we dont have enough shares. 🤑"  
[X Link](https://x.com/BIOTECHSCANNER/status/2016209944995880988)  2026-01-27T18:01Z [----] followers, [----] engagements


"$IOVA - Corleen Roche the new CFO immediately went to work to reduce headcount by 20% to right size the company. Now the company is hiring [--] Medical Science Liaisons (MSL) for the West tells me that Corleen has seen the demand significantly increased for her to approve this hiring. Whats this mean in pharmaceutical sales and marketing [--]. This is a large expansion because each MSL covers a large area. Since Amtagvi is a very specialized treatment each district covers very large areas. Hiring [--] MSL for West probably involves western states like California Washington Oregon Nevada New Mexico"  
[X Link](https://x.com/BIOTECHSCANNER/status/2016923357120286908)  2026-01-29T17:16Z [----] followers, [----] engagements


"Bill Gadless passed away Wednesday. He was still posting biotech contents on LinkedIn while he was in hospice care. Yet losers with a mobile device still harassing Bill. Hes an amazing person. This is why I dont tolerate bs from people. My mute and block buttons are always ready. Bill Gladless is one of the best person to follow on LinkedIn if youre interested in biotech. He is diagnosed with stage [--] esophageal cancer in October [----] but still puts out contents on a daily basis. Yet he cannot escape the ROACHES from social media. One of the comments https://t.co/NS2G3vRzrr Bill Gladless is"  
[X Link](https://x.com/BIOTECHSCANNER/status/2017431625739432228)  2026-01-31T02:55Z [----] followers, [----] engagements


"$IOVA - They will find it at $4 $5 $6 and $7 in 2026"  
[X Link](https://x.com/BIOTECHSCANNER/status/2018334371338453265)  2026-02-02T14:43Z [----] followers, [----] engagements


"$IOVA $AQST - If you are paying anyone for DD in biotech you are part of the EXCLUSION criteria for this trial. $AQST - New human factor trial inclusion and exclusion criteria Inclusion: Typical intelligence Exclusion: Dumbass $AQST - New human factor trial inclusion and exclusion criteria Inclusion: Typical intelligence Exclusion: Dumbass"  
[X Link](https://x.com/BIOTECHSCANNER/status/2018343337724371254)  2026-02-02T15:18Z [----] followers, [----] engagements


"@PistolOnFire44 Yep. Its a very dirty game SPRY played. Its ok. $SPRY is going to $4"  
[X Link](https://x.com/BIOTECHSCANNER/status/2018358469892452577)  2026-02-02T16:18Z [----] followers, [---] engagements


"$IOVA - This is my #1 biotech for 2026-2027. Currently trading basically at cash levels. No debt $300M cash a brand new cell manufacturing facility worth $1B; has the best and only TIL treatment in 2nd line metastatic melanoma. Treatment adoption is accelerating due to [--] year real world data showing tremendous efficacy. KOLs are endorsed Amtagvi and a true 2nd line treatment for metastatic melanoma. The next potential indication will be NSCLC in early [----]. Next generation TIL treatments are more powerful and for more types of solid cancers that make up 90% of all cancers. WE ARE WAY WAY WAY"  
[X Link](https://x.com/BIOTECHSCANNER/status/2018360769583231111)  2026-02-02T16:28Z [----] followers, [----] engagements


"$AQST $IOVA - Back due to popular demand @Dansfera and I will have a live podcast tomorrow at [--] pm ET [--] pm CST and [--] pm PST. We will discuss the homeless situation in this country due to shorts getting destroyed today. We need additional shelters and Goodwill stores across the country. Next segment is called We dont have enough shares for $IOVA and $AQST. I will be sharing something very bullish about $IOVA from the very top of management possibly the companys founder or related partner. YOU ABSOLUTELY DONT HAVE ENOUGH SHARES. $AQST - I will address EVERYTHING as always. Shorts chose the"  
[X Link](https://x.com/BIOTECHSCANNER/status/2018434633973604475)  2026-02-02T21:21Z [----] followers, [----] engagements


"$IOVA - Amtagvi is contributing to this cause. Soon we will be talking about [--] year survival because of Amtagvi and the next generation TILs that are coming. Yes we are early. https://www.linkedin.com/posts/robert-stone-ceo_according-to-the-american-cancer-society-activity-7418473926386966529-2bphutm_medium=ios_app&rcm=ACoAAAU2K7AByr5iaH05OD-JfkhMdYGafl2btt4&utm_source=social_share_send&utm_campaign=copy_link"  
[X Link](https://x.com/BIOTECHSCANNER/status/2018440259793486106)  2026-02-02T21:43Z [----] followers, [----] engagements


"Novo Nordisk stock is getting hammered. This is a big warning to those who are investing in GLP-1 companies. I have said this many times this year the compounding business and fierce competition will affect profitability big time. This is not to bash but this is from someone who has been in the industry and having launched multiple GLP-1 drugs. The GLP-1 market landscape has changed dramatically. You have to understand the changes on the ground. Conviction cannot be blind. New modalities for weight management are coming as well as the shift to small molecules and genetic engineering. You have"  
[X Link](https://x.com/BIOTECHSCANNER/status/2018739610806006065)  2026-02-03T17:33Z [----] followers, [----] engagements


"$IOVA - Amtagvi is the only treatment specifically indicated for 2nd line metastatic melanoma. The National Comprehensive Cancer Network (NCCN) recommends Amtagvi as a true second line treatment for metastatic melanoma. That means as soon as the patient has progressed to second line Amtagvi supposed to be used. Unfortunately this didnt happen and the company had to adjust full year sales guidance down over 40%. The stock tanked. There are several reasons oncologists hesitate to initiate Amtagvi immediately after frontline. [--]. Amtagvi is the first approved TIL treatment and most wanted to wait"  
[X Link](https://x.com/BIOTECHSCANNER/status/2018770506405519588)  2026-02-03T19:36Z [----] followers, [----] engagements


"$IOVA - Amtagvi just saved another life. Just another normal TILsday. No big deal. Like I said Amtagvi is now mainstream. Very well received and recommended by patients. Thats the best advertisement you can get. And its free https://youtu.be/yO-W-JMEvNssi=3JlTY-gNq5fRQokv https://youtu.be/yO-W-JMEvNssi=3JlTY-gNq5fRQokv"  
[X Link](https://x.com/BIOTECHSCANNER/status/2018797770635932090)  2026-02-03T21:24Z [----] followers, [----] engagements


"$IOVA - Have I told you TIL treatment is going mainstream Think globally next. What company has TIL treatment The one and only Iovance Biotherapeutics. Amtagvi is the only FDA approved TIL treatment in the world. The UK is getting ready to welcome TIL therapy soon. https://www.linkedin.com/posts/activity-7424447245476909056-hOCxutm_medium=ios_app&rcm=ACoAAAU2K7AByr5iaH05OD-JfkhMdYGafl2btt4&utm_source=social_share_send&utm_campaign=copy_link"  
[X Link](https://x.com/BIOTECHSCANNER/status/2018883904283857324)  2026-02-04T03:06Z [----] followers, [----] engagements


"$IOVA - Today is World Cancer Day. Iovance Biotherapeutics has the only FDA approved TIL therapy. This company is currently trading at near cash value and no debt. It has a pipeline that focuses on solid tumor cancer that makes up more than 90% of all new cancers. After releasing a [--] year real world retrospective study showing amazing and long lasting efficacy TIL therapy is getting recognized as an important treatment for melanoma. $IOVA will release the final data on the Non-Small Cell Lung Cancer (NSCLC) in Q3 or [--] of this year and possibly getting the Commissioner National Priority"  
[X Link](https://x.com/BIOTECHSCANNER/status/2019066224450146741)  2026-02-04T15:11Z [----] followers, [----] engagements


"$IOVA - Meet Jennifer. Look at what shes holding. Listen to what she said. So at that point I went on to TIL therapy. It was my last hope. Jennifer doesnt have any active cancer in her body. This is called No Evidence of Disease (NED). Coincidentally she was treated at the same hospital as Chris White @MucosalMelanoma Aurora CO at Anschultz Medical Center. This was not part of the clinical trial. Jennifer was treated as a commercial patient. Why do you think Key Opinion Leaders (KOLs) around the world are recommending Amtagvi Why do you think the company is expanding its sales force Increased"  
[X Link](https://x.com/BIOTECHSCANNER/status/2019103326671958453)  2026-02-04T17:38Z [----] followers, [----] engagements


"$IOVA - Shorts taking advantage of a bloody market. Let them in. FAFO"  
[X Link](https://x.com/BIOTECHSCANNER/status/2019150801478787287)  2026-02-04T20:47Z [----] followers, [----] engagements


"$IOVA - Misconceptions about Iovance Biotherapeutics still exist. [--]. Amtagvi works great only on a few patients so probably cant generate much revenue. FALSE. It works on a lot of patients. It actually works BETTER if the patients are put on Amtagvi sooner Currently Amtagvi is only approved for patients who have progressed after frontline treatments have failed them. These patients are classified as second line patients. Even though the population in second line is smaller there are tens of thousands of patients who can benefit from Amtagvi. Of course not every second line patient can receive"  
[X Link](https://x.com/BIOTECHSCANNER/status/2019427416309928329)  2026-02-05T15:06Z [----] followers, [----] engagements


"@Bailey13148 Not at all. Blood cancer. IOVA has stopped or slowed down to focus more on solid cancers. They were looking at PBL (peripheral blood) TIL for blood cancers but currently on pause"  
[X Link](https://x.com/BIOTECHSCANNER/status/2019431829569470752)  2026-02-05T15:24Z [----] followers, [---] engagements


"$IOVA - I have shared about [--] stories of patients who were cured by Amtagvi. These patients have [--] thing in common: Millions of dollars spent on chemotherapy radiation and immunotherapy (Immune Checkpoint Inhibitors) and what do they get A life time of lingering side effects and their cancer got worse. unTIL they received Amtagvi. The entire treatment cost about is $600K and nothing else to have to take for maintenance. Its a [--] time payment. And insurance PAY FOR IT if Amtagvi is on formulary. Many insurance have added Amtagvi on their formularies. Another thing that these melanoma survivors"  
[X Link](https://x.com/BIOTECHSCANNER/status/2019456090975662338)  2026-02-05T17:00Z [----] followers, [----] engagements


"$AQST $IOVA - I am not even looking at the sp today. How bad was it"  
[X Link](https://x.com/BIOTECHSCANNER/status/2019522154283622831)  2026-02-05T21:22Z [----] followers, [----] engagements


"$IOVA - New [--] year data continues to show best in class ORR and disease control rate. Remember these are very sick patients. This data is screaming out to oncologists to start patients on Amtagvi AS SOON AS frontline treatments failed. The word is getting out as this amazing data is spreading across the oncology community. https://ir.iovance.com/news-releases/news-release-details/best-class-real-world-data-support-early-amtagvir-treatment/ https://ir.iovance.com/news-releases/news-release-details/best-class-real-world-data-support-early-amtagvir-treatment/"  
[X Link](https://x.com/BIOTECHSCANNER/status/2019538230106841276)  2026-02-05T22:26Z [----] followers, [---] engagements


"$IOVA - New data continues to show best in class ORR and disease control rate. Remember these are very sick patients. This data is screaming out to oncologists to start patients on Amtagvi AS SOON AS frontline treatments failed. The word is getting out as this amazing data is spreading across the oncology community. https://ir.iovance.com/news-releases/news-release-details/best-class-real-world-data-support-early-amtagvir-treatment/ https://ir.iovance.com/news-releases/news-release-details/best-class-real-world-data-support-early-amtagvir-treatment/"  
[X Link](https://x.com/BIOTECHSCANNER/status/2019541691565301830)  2026-02-05T22:40Z [----] followers, [----] engagements


"Sell your BTC and load up $IOVA and $AQST. You are welcome. 😉"  
[X Link](https://x.com/BIOTECHSCANNER/status/2019570426175975824)  2026-02-06T00:34Z [----] followers, [----] engagements


"$IOVA - The oncology community is beginning to recognize Iovance Biotherapeutics as the leader in TIL therapy and solid tumor cancers. This data validates the recommendation by the National Comprehensive Cancer Network (NCCN) that Amtagvi is a true second line treatment for metastatic melanoma. Now when a patient has progressed from frontline to second line Amtagvi will come up as the next step. If not there better be a good reason or else it could be viewed as medical mal-practice. The National Comprehensive Cancer Network (NCCN) is an alliance of [--] leading cancer centers like MD Anderson"  
[X Link](https://x.com/BIOTECHSCANNER/status/2019608657051152567)  2026-02-06T03:06Z [----] followers, [----] engagements


"You know that almost all companies have existing ATMs right If your thesis on investing is based on ATMs and dilution then growth stocks are not for you. Did you know Palantir NVDA ASTS RKLB AMD all had ATMs when they started out Also how do you think $IOVA built the brand new state of the art manufacturing facility with no debt Dilution. That manufacturing facility is finished paid for. $IOVA is trading at cash value. The company has about [--] clinical trials right now. How do you think they will pay for it But soon they will generate billions a year with new approvals coming. Everyone wants"  
[X Link](https://x.com/BIOTECHSCANNER/status/2019614126994034778)  2026-02-06T03:28Z [----] followers, [---] engagements


"$IOVA - I sometimes take it for granted and fail to point out this fact: Amtagvi is getting these incredible results in second line metastatic melanoma patients. Frontline treatments like Keytruda and all other immunotherapies have surrendered ineffective. Amtagvi is an amazing living drug that serves as the last hope to many who are preparing themselves for hospice. Immunotherapy like Keytruda (pembrolizumab) has about 50% success rate IN FRONTLINE. Amtagvi is achieving 52% ORR in second line (stage [--] mostly) with patients who have been through [--] prior lines of treatment or fewer. Think"  
[X Link](https://x.com/BIOTECHSCANNER/status/2019781962248937822)  2026-02-06T14:35Z [----] followers, [----] engagements


"@RickWhe78169487 TILVANCE [---] is the study for that and final results will come in [----]. But it is FRUSTRATING that by the evidence from the real world Amtagvi should be made available to everyone in frontline as well. Bureaucracy at its worst. NOTHING IS BETTER THAN AMTAGVI. NOTHING"  
[X Link](https://x.com/BIOTECHSCANNER/status/2019788502594965913)  2026-02-06T15:01Z [----] followers, [---] engagements


"@Dancingtapas After Q4 earnings. I am very excited about this"  
[X Link](https://x.com/BIOTECHSCANNER/status/2019788640629485617)  2026-02-06T15:01Z [----] followers, [--] engagements


"@DrMakaryFDA Please make Amtagvi available to frontline metastatic melanoma patients. The real world evidence makes it clear that the sooner these patients get this TIL treatment the better they will get. You have expressed a common sense approach and allowing real world evidence this is a great opportunity for you to apply these principles. TILVANCE [---] wont be finished until [----]. Lets not wait until then.Saving lives cant wait sir. $IOVA https://ir.iovance.com/news-releases/news-release-details/best-class-real-world-data-support-early-amtagvir-treatment/"  
[X Link](https://x.com/BIOTECHSCANNER/status/2019791503460102361)  2026-02-06T15:13Z [----] followers, [---] engagements


"$IOVA - I used the phrase Build it and they will come today to make a point that Amtagvi treatment is so good that physicians and doctors will come. I forgot to mention hospitals. Well guess what We have another hospital added Amtagvi treatment. New TIL Therapy Brings Breakthrough Hope for Advanced Melanoma Patients in Oklahoma at OU Health Stephenson Cancer Center I dont just make up random stuff fam. https://www.ouhealth.com/blog/2026/february/new-til-therapy-brings-breakthrough-hope-for-adv/ https://www.ouhealth.com/blog/2026/february/new-til-therapy-brings-breakthrough-hope-for-adv/"  
[X Link](https://x.com/BIOTECHSCANNER/status/2019795880115675584)  2026-02-06T15:30Z [----] followers, [----] engagements


"@NouVisalsok @Henry431171040 Yes. IOV-4001 will destroy Keytruda as well. $15B price tag for $IOVA. Wayne Rothbaum wont sell it below $15B"  
[X Link](https://x.com/BIOTECHSCANNER/status/2019802570932249072)  2026-02-06T15:57Z [----] followers, [---] engagements


"$IOVA - I love what The University of Oklahoma Health said in their press release announcing Amtagvi treatment availability: Imagine being told no more options exist in your fight against cancer. For many Oklahomans with advanced melanoma treatment options were limited until now. It should be unTIL 😀 Amtagvi is the best and the last hope. If you invest in a biotech look for similar qualities in the current drugs and pipeline. You dont need to look. Its $IOVA. Youre welcome. https://www.ouhealth.com/blog/2026/february/new-til-therapy-brings-breakthrough-hope-for-adv/"  
[X Link](https://x.com/BIOTECHSCANNER/status/2019811446981296248)  2026-02-06T16:32Z [----] followers, [----] engagements


"@CanaryMktIntel Yes Thats why I said the other day that in a few years these data points will come to light. [--] year real world data will be [--] or [--] year real world data. Thank you"  
[X Link](https://x.com/BIOTECHSCANNER/status/2019815674034725078)  2026-02-06T16:49Z [----] followers, [---] engagements


"$IOVA - I said the other day that we will get [--] year real world data on Amtagvi. Oncologists have already seen long lasting results. @BIOTECHSCANNER from the same article: "This is a life-or-death situation for these patients" Dr. Al-Juhaishi said. "When it works it's thought to be curative. We have data showing patients [--] [--] even [--] years out from treatment who are still in remission." @BIOTECHSCANNER from the same article: "This is a life-or-death situation for these patients" Dr. Al-Juhaishi said. "When it works it's thought to be curative. We have data showing patients [--] [--] even 20"  
[X Link](https://x.com/BIOTECHSCANNER/status/2019816293713825930)  2026-02-06T16:51Z [----] followers, [----] engagements


"If you have followed Wayne Rothbaum he always sells his companies to BP. This is why $IOVA doesnt take on debt to make acquisition easier. But either buyout or not shareholders stand to gain if they are patient. No drugs or treatments become blockbuster overnight. Amtagvi will be a blockbuster drug soon. https://twitter.com/i/web/status/2019839554820223228 https://twitter.com/i/web/status/2019839554820223228"  
[X Link](https://x.com/BIOTECHSCANNER/status/2019839554820223228)  2026-02-06T18:24Z [----] followers, [---] engagements


"$AQST $IOVA - Have a great weekend 🐉 family. Even though $AQST timeline has been pushed back the final destination is the same- approval of Anaphylm. For $IOVA - Theres no biotech that has as many catalysts as Iovance Biotherapeutics. The biggest catalyst is seeing progress in [--] critical areas in Q4 earnings to absolutely burn shorts. [--]. Increase revenue for Amtagvi and Proleukin. This shows demand and adoption. [--]. Margins improvements. We should see margins getting better as more true second line patients get on Amtagvi. Second line patients who were prescribed Amtagvi immediately after"  
[X Link](https://x.com/BIOTECHSCANNER/status/2019910995322290239)  2026-02-06T23:08Z [----] followers, [----] engagements


"Im pretty sure LN-145 will be in Q2 which is great. They should spread out the catalysts. IOV-4001 is specifically scheduled for Q1. AACR is where it will be presented and a PR will follow. Just my prediction. Since Dr. Gastman will be presenting some type of data at AACR its more likely about IOV-4001 since this is a genetically engineered TIL and hes an expert on translational genetics. Previous IOV-4001 data was also presented at the same conference. IOV-4001 is also further along than LN-145. Maybe before Q2 earnings for LN-145. https://twitter.com/i/web/status/2020222999316611477"  
[X Link](https://x.com/BIOTECHSCANNER/status/2020222999316611477)  2026-02-07T19:47Z [----] followers, [--] engagements


"$IOVA - Iovance Biotherapeutics announced last summer that it is partnering with InspiroGene by McKesson to be a specialty pharmacy for all Authorized Treatment Centers (ATCs). InspiroGene takes care of all pre-authorization logistics for patients. More importantly ATCs dont have to buy Amtagvi and Proleukin from Iovance pay first and risking not getting reimbursed by insurance. All this will be taken care of by InspiroGene a division of McKesson that focuses on complex treatments for cell and gene therapy. So $IOVA partners with McKesson Corporation a global leader in healthcare services and"  
[X Link](https://x.com/BIOTECHSCANNER/status/2020578802255245477)  2026-02-08T19:21Z [----] followers, [----] engagements


"$IOVA - InspiroGene introduces Biologics in a Box to fine tune logistics for cell and gene therapy. Partnership with InspiroGene is a game changer for Iovance. Its more than just drug delivery. Its the entire treatment journey for the patient from initial referral to after care and reimbursement for providers. InspiroGenes specialty pharmacy does everything. With Amtagvi being recognized as standard of care in second line metastatic melanoma demand will increase. Its a perfect time to remove the bottlenecks that slowed Amtagvis adoption last year. I am very excited for [----] as more community"  
[X Link](https://x.com/BIOTECHSCANNER/status/2020921120413954128)  2026-02-09T18:01Z [----] followers, [----] engagements


"$IOVA - The last hope for the hopeless. This is the only biotech you will need for the next [--] years. Just getting started. McKesson doesnt partner with a random company. $IOVACis a monster in the making. The world is waking up to the best and only TIL treatment specifically indicated for second line metastatic melanoma. Nothing else. https://www.linkedin.com/posts/aim-at-melanoma_melanoma-tiltherapy-cancerresearch-activity-7426671360627621888-FPxZutm_medium=ios_app&rcm=ACoAAAU2K7AByr5iaH05OD-JfkhMdYGafl2btt4&utm_source=social_share_send&utm_campaign=copy_link"  
[X Link](https://x.com/BIOTECHSCANNER/status/2020955168993575041)  2026-02-09T20:17Z [----] followers, [----] engagements


"$IOVA - Iovance is expanding. I have seen quite a few new hirings lately. This is really good to see. I think demand has picked up significantly as expected. Oncologists are much more comfortable with Amtagvi. Remember the treatment is very complex and expensive. However Amtagvi is WORTH EVERY PENNY. Its a one time treatment that requires no maintenance therapy Think about all the down stream costs being saved. Insurance companies are finally recognizing the true value a [--] time treatment really is. Other treatments ended up being much more expensive than Amtagvi and the patients ultimately"  
[X Link](https://x.com/BIOTECHSCANNER/status/2021037524672537032)  2026-02-10T01:44Z [----] followers, [----] engagements


"@alexanderjgallo They could be a farmer from BMT Vietnam for all we know"  
[X Link](https://x.com/BIOTECHSCANNER/status/2021593888926880198)  2026-02-11T14:35Z [----] followers, [--] engagements


"$IOVA - Another hiring position posted. Things seem to be going really well. Lots of hirings lately. https://www.linkedin.com/posts/laurel-todd-6806933_director-us-health-economic-value-access-activity-7427769799511928832-6L37utm_medium=ios_app&rcm=ACoAAAU2K7AByr5iaH05OD-JfkhMdYGafl2btt4&utm_source=social_share_send&utm_campaign=copy_link https://www.linkedin.com/posts/laurel-todd-6806933_director-us-health-economic-value-access-activity-7427769799511928832-6L37utm_medium=ios_app&rcm=ACoAAAU2K7AByr5iaH05OD-JfkhMdYGafl2btt4&utm_source=social_share_send&utm_campaign=copy_link"  
[X Link](https://x.com/BIOTECHSCANNER/status/2022005031294079438)  2026-02-12T17:49Z [----] followers, [----] engagements


"$IOVA - The expansion continues. Introducing Nancy Ledinsky Associate Director Cell Therapy Account Manager. She and I worked at the same company previously. We were not there together though. She left Replimune (REPL) for $IOVA [--] months ago. Smart move Its going to be fun for the next couple of years and beyond"  
[X Link](https://x.com/BIOTECHSCANNER/status/2022742999646769648)  2026-02-14T18:41Z [----] followers, [----] engagements


"On July [--] [----] the share price of $ARQT was $9.30. I predicted that it could hit $18-$25. I was wrong. It only got to $13.93 on 12/31/2024. But today its at $30. Maybe I know something about the pharmaceutical industry 😆. I have said that $AQST and $IOVA will both be in the teens levels. It will come. $ARQT - My end of year PT is $18-25. I am anticipating the up coming approval for atopic dermatitis to propel the company into an accelerated growth phase financially and the next big indication will come soon scalp and body psoriasis. They also have biologics in the pipeline as $ARQT - My end"  
[X Link](https://x.com/BIOTECHSCANNER/status/1998532255153578191)  2025-12-09T23:16Z [----] followers, [----] engagements


"$AQST - Last month I said Rocket Lab will be $75 by December [--] [----]. It did. My entry was $44.99. It jumped to $86 yesterday. On July [--] [----] I predicted that $ARQT will be at $18 to $25 after approval of Zoryve for atopic dermatitis when the share price was $9.30. It got to $31.20 on12/5/2025. Here I am telling everyone $AQST will be at least $15 to $18 after Anaphylm gets approved and if launch is successful. The launch will absolutely be successful with Sherry Korczynski in charge. This is not a binary investment. Just like $ARQT $AQST will generate so much cash with Anaphylm. Even better"  
[X Link](https://x.com/BIOTECHSCANNER/status/2008963999908724911)  2026-01-07T18:08Z [----] followers, [----] engagements


"$AQST - Worst case scenario that actually happened to $SPRY. [--]. 9/19/2023 share price $6.60 [--]. 9/20/2023 share price $2.92 [--]. 1/23/2024 (4 months later) $6.77 [--]. 8/9/2024 (approval [--] months after CRL) $10.88 [--]. 11/11/2024 (3 months after approval) $17.49 high of $18.51 I have brought up this situation many times that even IF a CRL is given to Aquestive. The company will work with the FDA to get Anaphylm approved. Thats exactly what happened with SPRY. I dont think AQST will get a CRL though. I will touch on this more on the podcast at [--] pm ET today."  
[X Link](https://x.com/BIOTECHSCANNER/status/2009763700991807947)  2026-01-09T23:06Z [----] followers, [----] engagements


"$IOVA - Keytruda(pembrolizumab) is the most commercially successful cancer drug and third in all drugs. Lifetime estimated revenue: [--]. Humira - Immunology - $220B [--]. Lipitor - Cholesterol- $160B [--]. Keytruda - Oncology- $120B Keytruda is an immunotherapy drug in the class of drugs called Immune Checkpoint Inhibitor (ICI). Keytruda is a miracle drug for cancer of many types. But unfortunately 50% of cancer patients still get worse after a while. There are many ICIs on the market. In 2nd line metastatic melanoma stage [--] and [--] theres nothing else except Amtagvi a Tumor-Infiltrating Lymphocyte"  
[X Link](https://x.com/BIOTECHSCANNER/status/2018808015403757762)  2026-02-03T22:05Z [----] followers, [----] engagements


"Everything will go back to all time highs the moment President Trump withdrawing his nomination of Kevin Warsh. I THINK HE WILL"  
[X Link](https://x.com/BIOTECHSCANNER/status/2019527579095691670)  2026-02-05T21:44Z [----] followers, [----] engagements


"$IOVA - State Street Corp increases almost [--] million shares today. This is less than [--] weeks before Q4 earnings. Hmm"  
[X Link](https://x.com/BIOTECHSCANNER/status/2020839349299171700)  2026-02-09T12:37Z [----] followers, [----] engagements


"$IOVA - Amtagvi is working miracles every day for patients with no options remaining in second line metastatic melanoma. Retrospective study shows the sooner patients get Amtagvi the better off they will be. Key opinion leaders at leading academic hospitals are encouraging oncologists to follow the NCCN guidelines that is to use Amtagvi as a true second line treatment. This is why demand for Amtagvi will accelerate big time in [----] and beyond. What about Non-small cell lung cancer (NSCLC) This will be the next indication for Amtagvi. On November [--] [----] $IOVA reported 26% Objective Response"  
[X Link](https://x.com/BIOTECHSCANNER/status/2021271306793025863)  2026-02-10T17:13Z [----] followers, [----] engagements


"$IOVA - Its getting really exciting here. This webcast by hosted by ION Oncology on Thursday February [--] [----] at 1:00 PM ET 12:00 PM CT. ION Oncology Practice Network a specialty GPO and is specifically designed for healthcare providers and network members. Webcast Highlights Topic: Therapy for Advanced Melanoma. Key Speaker: Dr. Elie Fahed a Hematologist and Oncologist from Rocky Mountain Oncology. Core Objectives: [--]. Reviewing the clinical efficacy and safety profile of Iovances approved cell therapy Amtagvi. [--]. Discussing patient selection and clinical eligibility for TIL (Tumor"  
[X Link](https://x.com/BIOTECHSCANNER/status/2021358928605421588)  2026-02-10T23:01Z [----] followers, [----] engagements


"Lots of fake pharmacists on X. Be careful 🚨BREAKING: Police in India arrested (11) people who issued over (100K) fake university degrees in medicine nursing & engineering How many of these people are in a medical practice or engineering firm here in America https://t.co/iRLrSlMes3 🚨BREAKING: Police in India arrested (11) people who issued over (100K) fake university degrees in medicine nursing & engineering How many of these people are in a medical practice or engineering firm here in America https://t.co/iRLrSlMes3"  
[X Link](https://x.com/BIOTECHSCANNER/status/2021575570585243725)  2026-02-11T13:22Z [----] followers, [----] engagements


"$IOVA - No one knows more about Amtagvi and its side effects safety efficacy patient quality of life cost and value proposition than Dr. Allison Betof Warner. The first patient treated with Amtagvi after the February [--] [----] FDA approval was her In this video Dr. Betof-Warner will explain everything about melanoma and Amtagvi. This is the most informative video about Amtagvi that you will ever see. Guess what she mentioned in this video [--]. Melanoma is deadly [--]. Chemotherapy doesnt do much [--]. Immunotherapy works great but many will not respond or respond at first but will progress to stage 3"  
[X Link](https://x.com/BIOTECHSCANNER/status/2021632207706620159)  2026-02-11T17:07Z [----] followers, [----] engagements


"$IOVA - IO360 Summit on February [--] [----] at 4:10pm ET. That is 1h [--] minutes from now"  
[X Link](https://x.com/BIOTECHSCANNER/status/2021688513150804314)  2026-02-11T20:51Z [----] followers, [----] engagements


"$IOVA - Q4 earnings call will be on February [--] [----] at 8:30 AM ET. This is only the second time the company is reporting earnings pre-market. Watch out shorts . Great earnings last time https://ir.iovance.com/news-releases/news-release-details/iovance-biotherapeutics-report-fourth-quarter-and-full-year-2025/ https://ir.iovance.com/news-releases/news-release-details/iovance-biotherapeutics-report-fourth-quarter-and-full-year-2025/"  
[X Link](https://x.com/BIOTECHSCANNER/status/2021693251401461904)  2026-02-11T21:10Z [----] followers, [----] engagements


"@Dancingtapas I think we may reach [---]. If we did shorts are 💀"  
[X Link](https://x.com/BIOTECHSCANNER/status/2022040480461336927)  2026-02-12T20:09Z [----] followers, [--] engagements


"I agree. Q3 was a first step towards the greener pasture my friend. I think Q1 [----] earnings is when we see the company making leaps and bounds. Oncologists who dont refer their patients to get Amtagvi immediately will be an outlier. They will be questioned. The narrative has changed. https://twitter.com/i/web/status/2022067000189612428 https://twitter.com/i/web/status/2022067000189612428"  
[X Link](https://x.com/BIOTECHSCANNER/status/2022067000189612428)  2026-02-12T21:55Z [----] followers, [---] engagements


"Be careful with that one. I dont like it when the CEO acts like an OTC company. Making while claims about curing all cancers. Its an IL-15 agonist. Not an IL-15 super agonist for goodness sake. If you like that you would love IOV-5001. Thats TIL armed with IL-12. Way more powerful than that Antikva"  
[X Link](https://x.com/BIOTECHSCANNER/status/2022139882324287872)  2026-02-13T02:44Z [----] followers, [--] engagements


"RT @JanvDes: @savallsicart @BIOTECHSCANNER https://x.com/JanvDes/status/2021285180321738923 https://x.com/JanvDes/status/2021285180321738923"  
[X Link](https://x.com/BIOTECHSCANNER/status/2022740360045420686)  2026-02-14T18:30Z [----] followers, [--] engagements


"$IOVA - The world is recognizing Iovance Biotherapeutics as an innovative company. Making life saving drugs for patients running out of options. Blockbuster drugs dont happen overnight. It takes hard work to make adoption happen. Its happening. There is no biotech company that is more exciting than $IOVA for the next [--] years. https://www.linkedin.com/posts/melissa-hibdon_so-very-proud-to-lead-this-team-with-dr-sherif-ugcPost-7427174515023118336-mvWdutm_source=social_share_send&utm_medium=ios_app&rcm=ACoAAAU2K7AByr5iaH05OD-JfkhMdYGafl2btt4&utm_campaign=copy_link"  
[X Link](https://x.com/BIOTECHSCANNER/status/2021581872451481865)  2026-02-11T13:47Z [----] followers, [----] engagements


"$IOVA - This clip is from the IO360 conference yesterday. It was only for healthcare professionals who can join the webcast. I dont have one for when COO of Iovance spoke. But in this clip you will hear Dr. Eric Tran who is a T-cell expert talking about different ways of manipulating T-cells to fight cancer. Really cool to see a Vietnamese scientist who is an expert on T-cells. Toward the end he talked about TIL. He brought up a unique feature of TIL that CAR-T doesnt have and this makes it effective in solid tumors whereas CAR-T is ineffective and that is its POLYCLONAL quality. I have"  
[X Link](https://x.com/BIOTECHSCANNER/status/2021954544939262384)  2026-02-12T14:28Z [----] followers, [----] engagements


"$IOVA - FY [----] guidance is $250M-$300M. Q1: $49.3 Q2: $60M Q3: $68M So far its $177.3M revenue To reach $250 Q4 needs to be at $72.7 To reach $300M Q4 needs to get to $122.7M We should be good at $72.7 but I would love to see $100M and margins around 55%. If we see $450-$500M for [----] guidance shorts are screwed. I think management will give a conservative guidance so they can blow it out of the water. They have learned their lesson. I like the new CFO a lot. Corleen Roche will do a great job at Iovance. https://twitter.com/i/web/status/2022056415699861900"  
[X Link](https://x.com/BIOTECHSCANNER/status/2022056415699861900)  2026-02-12T21:13Z [----] followers, [----] engagements


"Happy Valentines Day Hope youre enjoying quality time with your loved ones About to get some delicious Cajun seafood Vietnamese style at a place called The Boiling Crab. This place originates in California but makes it to Texas. There are [--] locations near me. Love their live crawfish and everything else 😂"  
[X Link](https://x.com/BIOTECHSCANNER/status/2022828459844628722)  2026-02-15T00:21Z [----] followers, [----] engagements


"$AQST - Who are the smartest investors in [----] The entire $SPRY management. One of them sold his entire holdings while others also unloaded shares as well. In November [----] Justin Chakma the Chief Business Officer (CBO) of ARS Pharmaceuticals (NASDAQ: SPRY) reportedly sold his entire direct shareholding in the company. While multiple executives have sold shares throughout [----] Chakma's transactions were notable because they resulted in his direct ownership dropping to zero. Justin Chakma Sale Transaction Date: November [--] [----]. Total Shares Sold: Approximately [------] shares for a total value"  
[X Link](https://x.com/BIOTECHSCANNER/status/2005046297217138698)  2025-12-27T22:41Z [----] followers, [----] engagements


"$AQST - One of my biggest regrets this year was selling $ARQT too soon. I researched this company for months and released it at $8.84 last year. Their lead product Zoryve foam (roflumilast topical foam 0.3%) was first approved by the FDA for seborrheic dermatitis. Then it received a supplemental FDA approval for plaque psoriasis of the scalp and body. It went to $31.77 on December [--] [----]. This is the reason that I dont need to add new tickers. I have zero interest in growing the follower count. It means nothing to profitability. It is much more important to find FEW solid companies and let"  
[X Link](https://x.com/BIOTECHSCANNER/status/2005333455349874862)  2025-12-28T17:42Z [----] followers, [----] engagements


"$IOVA - I keep going back to using the Tesla story and how it mirrors Iovance Biotherapeutics journey so far. When Tesla said it will be making electric vehicles everyone said it couldnt be done. Theres no EV manufacturing facility big enough to scale. Theres no charging infrastructure. Its too expensive. The company will not survive. Indeed things look bleak for a while and Tesla almost went bankrupt. It finally produced its first EV- the Tesla Roaster. It loses money on every one sold. Then came Model S X and still losing money. Its not until the model [--] that Tesla finally made a profit"  
[X Link](https://x.com/BIOTECHSCANNER/status/2021231730393260321)  2026-02-10T14:36Z [----] followers, [----] engagements


"$AQST - The only thing that we as investors can do is to wait until the company gives us the details after they meet with the FDA. ANYTHING that I or anyone else say before that is pure speculations and opinions. We all have the right to do so. However I have been sent screenshots of StockTwits that manipulative shorts and day traders are out in full force. This is why I have stressed to DELETE this app. Also what you will find on StockTwits is that the biggest bashers are manipulative shorts and day traders wanting cheap shares. How do I know this Just pick any frequent bashers and you will"  
[X Link](https://x.com/BIOTECHSCANNER/status/2011117525715603550)  2026-01-13T16:45Z [----] followers, [----] engagements


"$AQST - Since we are still waiting to hear from the FDA or the company lets set the facts straight on the comparison between Anaphylm and Neffy. [--]. Both Anaphylm and Neffy are way better than the needle based options like EpiPen [--]. Anaphylm being a non-device and oral option makes it an easy choice over the nasal spray Neffy. So how do we know which option will win commercially ARS Pharma Inc the maker of Neffy filed a citizen petition asking the FDA to delay approval of Anaphylm scheduled to be on 1/31/2026. ARS Pharma is absolutely terrified of Anaphylms approval. Insiders from ARS have"  
[X Link](https://x.com/BIOTECHSCANNER/status/2015110385632706962)  2026-01-24T17:12Z [----] followers, [----] engagements


"$AQST- The FDA sucks. They should have approved Anaphylm. The should ask all of the EpiPens to redo human factor trial again to see if people can inject themselves correctly"  
[X Link](https://x.com/BIOTECHSCANNER/status/2018308444290265308)  2026-02-02T13:00Z [----] followers, [----] engagements


"$IOVA - Lets look at another next generation TIL. An Investigational New Drug (IND) submission is planned in early [----] for IOV-5001. What is IOV-5001 IOV-5001 is a genetically armored TIL. Unlike traditional TIL like Amtagvi which is simply harvested and expanded IOV-5001 is engineered to express interleukin-12 (IL-12) in a very specific way. [--]. Tethered IL-12: The IL-12 is tethered to the surface of the T-cell. [--]. Inducible Expression: It only activates when the T-cell actually engages with a cancer antigen. This on-demand system is designed to kill the tumor effectively without the toxic"  
[X Link](https://x.com/BIOTECHSCANNER/status/2021249282917933471)  2026-02-10T15:45Z [----] followers, [----] engagements


"$IOVA - This video was released [--] minutes ago. Recently I have been telling you that the narrative around TIL treatment with Amtagvi has changed dramatically among oncologists especially since the release of the [--] year real world data showing amazing efficacy and safety. But the key finding is the sooner the patient gets Amtagvi after JUST ONE or TWO TREATMENTS the better. You dont have to believe me. Lets hear it from an oncologist DEMAND FOR AMTAGVI WILL INCREASE FOR YEARS TO COME. https://youtu.be/cfGChGbNUGEsi=JLjs4Ez-dt9NziCE https://youtu.be/cfGChGbNUGEsi=JLjs4Ez-dt9NziCE"  
[X Link](https://x.com/BIOTECHSCANNER/status/2021287554046132279)  2026-02-10T18:18Z [----] followers, [----] engagements


"$IOVA - This may be the most satisfying and rewarding investment Ive ever made. This is the only company that I absolutely love doing research on besides $AQST. I truly hope that this company will continue to move forward with its mission to beat solid tumor cancers. I feel like the company is having a massive turn around. The oncology community is now seeing Amtagvi as a true second line treatment. Yesterday in the video the oncologist said right after the patient stopped responding to [--] frontline treatment she would put that patient on Amtagvi where as in the past she would have waited and"  
[X Link](https://x.com/BIOTECHSCANNER/status/2021702498801623248)  2026-02-11T21:46Z [----] followers, [----] engagements


"$IOVA - In the pharmaceutical industry every company large or small wants one thing when they launch a new drug: They want that drug to be top of mind when doctors are making prescribing decisions. For the past [--] months I have seen the narrative around Amtagvi changing from complex intensive harsh to the sooner we can get patients on Amtagvi the better off the patients will be. Amtagvi treatment starts out as a fringe and last resort treatment to as soon as possible is game changing for the company. It is the sound of the cash register ringing but much more frequently. This is a dream"  
[X Link](https://x.com/BIOTECHSCANNER/status/2021971757544992885)  2026-02-12T15:36Z [----] followers, [----] engagements


"$IOVA - Another hiring position posted. Facilities Engineer. Getting ready for Iovance Cell Therapy Center (iCTC)"  
[X Link](https://x.com/BIOTECHSCANNER/status/2022090991503913457)  2026-02-12T23:30Z [----] followers, [----] engagements


"$IOVA - The current FDA administration has put big and small pharma in a precarious situation. Theres so much inconsistency and mistrust. It seems previous alignment is as steady as the candle in the wind. On one side of the FDAs mouth it speaks of removing regulatory barriers but on the other side it keeps sending out CRLs like Christmas cards. Dr. Makary speaks of encouraging innovation and bringing manufacturing to the US as a national priority to combat the meteoric rise of China in the biotech sector. But Dr. Vinay Prasads rejection to review Modernas BLA for its new flu vaccine even"  
[X Link](https://x.com/BIOTECHSCANNER/status/2023096842825691193)  2026-02-15T18:07Z [----] followers, [----] engagements


"How to identify great biotech companies. Also my track record below. [--]. Undervalued (low market cap vs assets and market potential) [--]. Solid management (biotech experience CEO track record and reputation not too many turnovers) [--]. Great pipeline versus whats currently available (look for first and only or best in class potential. [--]. Solving a big unmet need [--]. Incremental successes through various stages of clinical trials [--]. Strong upcoming catalysts [--]. Positive interactions with FDA [--]. Buyout or partnership potential [--]. Similar compounds performing successfully on the market [--]. Current"  
[X Link](https://x.com/BIOTECHSCANNER/status/1810008082837119416)  2024-07-07T17:48Z [----] followers, 223.3K engagements


"$IOVA - If Q4 earnings shows progress in revenue and margins (I am very confident that it will) my shares will be locked up for at least another two years. I think we have something very special here. Heres what you are benefiting from buying at these levels: [--]. No debt [--]. A brand new state of the art cell manufacturing facility that is paid for and worth $900M to $1B. This is almost the entire market cap [--]. The bad launch execution of Amtagvi allows us to buy at bottom prices rather than $18.80 after Amtagvi was approved. [--]. The drastic share price correction was mostly due to the adjustment"  
[X Link](https://x.com/BIOTECHSCANNER/status/2022329252671021499)  2026-02-13T15:17Z [----] followers, [----] engagements


"$IOVA - I have said it several times before I believe AstraZeneca is paying very close attention to Iovances progress. AstraZeneca decided [--] years ago to go in hot and heavy with oncology and more specifically cell therapy. There is a HUGE and very significant relationship between the two companies. The biggest connection is the relationship between the Iovance Biotherapeutics largest shareholder and Director of the Board Wayne Rothbaum and AstraZenecas current CEO Sir Pascal Soriot. In one of the largest biotech deals of the previous decade Wayne Rothbaum co-founded and served as the"  
[X Link](https://x.com/BIOTECHSCANNER/status/2023173038510858377)  2026-02-15T23:10Z [----] followers, [--] engagements


"$AQST - The ATM raised of $21.4 million was to [--] institutional investors. One of them is a current investor"  
[X Link](https://x.com/BIOTECHSCANNER/status/1897639680637596129)  2025-03-06T13:25Z [----] followers, [----] engagements


"$CALT - If approved today will be huge for revenues for years to come. Calliditas Therapeutics is also seeking approval in Asia. China has huge market for CKD Type IgA. Already conditionally approved in South Korea and Europe"  
[X Link](https://x.com/BIOTECHSCANNER/status/1737529099726233707)  2023-12-20T17:43Z [----] followers, [----] engagements


"For the record since November of [----] I am 4-0 on PDUFA predictions. $CALT $ARQT $IONS $IOVA. I also predicted that $FUSN would be bought by $AZN for $3-5 billion. I was wrong on that one. $FUSN was bought out by $AZN for only $2.4 billion. For $VKTX I released at $12 my average was $11.60. I warned shorts to get out after they shorted it at $25. I told them that phase [--] data would be good and they will get destroyed if they short it. Well data was best in class and $VKTX went to $99.41. Hopefully they got out https://twitter.com/i/web/status/1782796391858721271"  
[X Link](https://x.com/BIOTECHSCANNER/status/1782796391858721271)  2024-04-23T15:39Z [----] followers, 11.9K engagements


"$ARQT - Amgen definitely has Arcutis Biotherapeutics on their radar. $AMGN has a pill form in the PDE4 inhibitor class called Otezla (apremilast) with a horrible side effect profile and confusing dosing schedule and twice daily dosing 😱. Now compare to the once daily topical foam. Fast acting and a much better safety profile. Check out the prescribing information. Buyout here is very possible. https://www.pi.amgen.com/-/media/Project/Amgen/Repository/pi-amgen-com/Otezla/otezla_pi_english.pdf https://www.pi.amgen.com/-/media/Project/Amgen/Repository/pi-amgen-com/Otezla/otezla_pi_english.pdf"  
[X Link](https://x.com/BIOTECHSCANNER/status/1805994308316676200)  2024-06-26T15:59Z [----] followers, [----] engagements


"Its got a dual PDE4 and [--] inhibitors in an inhalation form. The pill form Daliresp (Roflumilast) PDE-4 mono inhibitor already failed with AstraZeneca. They sold the drug and now Arcutis Biotherapeutics $ARQT is making a killing on it for Psoriasis with a drug called Zoryve. Someones trash is someone elses treasure Now go try to find someone with this kind of DD 😆. Oh and its free. https://twitter.com/i/web/status/1806433697693933778 https://twitter.com/i/web/status/1806433697693933778"  
[X Link](https://x.com/BIOTECHSCANNER/status/1806433697693933778)  2024-06-27T21:05Z [----] followers, [---] engagements


"$ARQT- They are hiring a lot of Medical Liasons due to anticipation of approval for atopic dermatitis. These people work with physicians and nurses to address questions and concerns due to the new indication."  
[X Link](https://x.com/BIOTECHSCANNER/status/1808196662986526939)  2024-07-02T17:50Z [----] followers, [----] engagements


"$ARQT - This is a very fair article to read. They laid out the risks and benefits. Their conclusions is mostly the company is undervalued. Price targets are given from $17.33 to $28.70. Please read. https://seekingalpha.com/article/4687904-arcutis-biotherapeutics-betting-big-on-zoryve https://seekingalpha.com/article/4687904-arcutis-biotherapeutics-betting-big-on-zoryve"  
[X Link](https://x.com/BIOTECHSCANNER/status/1810791576110518733)  2024-07-09T21:42Z [----] followers, [----] engagements


"$ARQT - On June [--] [----] Arcutis Biotherapeutics presented at Goldman Sachs 45th Annual Global Healthcare Conference. Please listen to the webcast. There are so many great nuggets here. Here are a few: [--]. The company will probably announce a partnership to promote Zoryve in primary care clinics. They are currently in talks with several companies. They prefer a company with a large sales force and able to focus on Zoryve as utmost priority. CEO mentioned they have a few that will fit what they want. End of [----] or first part of [----]. This will increase their sales potential by 50% because half"  
[X Link](https://x.com/BIOTECHSCANNER/status/1810868010015449397)  2024-07-10T02:45Z [----] followers, [----] engagements


"$ARQT - Heres the link to the conference call in [--] minutes https://investors.arcutis.com/events/event-details/arcutis-biotherapeutics-inc-q2-2024-earnings-conference-call/ https://investors.arcutis.com/events/event-details/arcutis-biotherapeutics-inc-q2-2024-earnings-conference-call/"  
[X Link](https://x.com/BIOTECHSCANNER/status/1823815027926991321)  2024-08-14T20:12Z [----] followers, [----] engagements


"$ARQT - Needham buy rating $18 price target. https://m.fastbull.com/news-detail/arcutis-biotherapeutics-price-target-maintained-with-a-1800share-news_7200_0_2024_3_47369_2/NASDAQ-ARQT https://m.fastbull.com/news-detail/arcutis-biotherapeutics-price-target-maintained-with-a-1800share-news_7200_0_2024_3_47369_2/NASDAQ-ARQT"  
[X Link](https://x.com/BIOTECHSCANNER/status/1824059816156815403)  2024-08-15T12:25Z [----] followers, [----] engagements


"$ARQT - TD Cowen buy rating price target $20. Its https://www.moomoo.com/news/post/41126064/td-cowen-maintains-arcutis-biotherapeutics-arqtus-with-buy-rating-maintains https://www.moomoo.com/news/post/41126064/td-cowen-maintains-arcutis-biotherapeutics-arqtus-with-buy-rating-maintains"  
[X Link](https://x.com/BIOTECHSCANNER/status/1824073069503066592)  2024-08-15T13:18Z [----] followers, [----] engagements


"$ARQT - Morgan Stanley maintains a buy rating moving price target from $18 to $19 https://www.moomoo.com/news/post/41470953/morgan-stanley-maintains-arcutis-biotherapeutics-arqtus-with-buy-rating-raises https://www.moomoo.com/news/post/41470953/morgan-stanley-maintains-arcutis-biotherapeutics-arqtus-with-buy-rating-raises"  
[X Link](https://x.com/BIOTECHSCANNER/status/1824073805343461423)  2024-08-15T13:20Z [----] followers, [----] engagements


"@Fire_Truck5 I predicted Fusion Pharmaceuticals to be bought out by AstraZeneca last January. They did an offering in February then a month later this happened https://www.astrazeneca.com/media-centre/press-releases/2024/astrazeneca-to-acquire-fusion.html https://www.astrazeneca.com/media-centre/press-releases/2024/astrazeneca-to-acquire-fusion.html"  
[X Link](https://x.com/BIOTECHSCANNER/status/1860389771471634753)  2024-11-23T18:27Z [----] followers, [--] engagements


"$ARQT - Arcutis Biotherapeutics is one of the few pure dermatology companies with a pipeline that includes multiple clinical programs evaluating PDE4 JAK1 and CD200R agonists for a range of inflammatory dermatological conditions. It is a commercial stage company that is making tremendous growth through the Zoryve franchise (foam and cream) for seborrheic dermatitis atopic dermatitis and plaque psoriasis. The company announced that the Supplemental New Drug Application (sNDA) for ZORYVE foam accepted by Food & Drug Administration (FDA) for the treatment of scalp and body psoriasis in adults"  
[X Link](https://x.com/BIOTECHSCANNER/status/1881194018060607681)  2025-01-20T04:16Z [----] followers, [----] engagements


"$IOVA - Bought the book This is the story of a stage [--] melanoma survivor who was the LAST patient admitted in the trial for Amtagvi in [----]. He joined our podcast yesterday with @dansfera . Dan already bought the book. I already know the story but cant wait to read the book TIL therapy IS THE FUTURE of cancer treatment Why do you think many oncologists incorrectly using Amtagvi as the last line of defense instead of using it sooner Because theres NOTHING else behind Amtagvi. I believe the new mindset coming from key opinion leaders in oncology is recognizing the true benefits of Amtagvi when"  
[X Link](https://x.com/BIOTECHSCANNER/status/1973415796782080075)  2025-10-01T15:52Z [----] followers, [----] engagements


"$IOVA - Corleen Roche CFO when answering the question of what drew her to Iovance even though she has a long track record at some large companies like Pfizer and Biogen and CG Oncology said I am very excited to be here and tell you all the good things that drew me to Iovance. Number [--] we cant forget the product is good its on the market and its helping people. Thats the most important thing. I believe the company is in good hands with her. Corleen Roche is very frank and honest. She has launched some big drugs before. Im very impressed by her previous success. Patience 🐉"  
[X Link](https://x.com/BIOTECHSCANNER/status/1976738115663303080)  2025-10-10T19:54Z [----] followers, [----] engagements


"$AQST - Take a listen to the Piper Sandler Conference if you havent. Very informative. Anaphylm launch readiness activities are in full swing. One thing that they talked about that I have not touched on is the work of the Medical Science Liasons (MSLs). Before a drug gets approved and if the company feels confident that it will they will hire MSLs. This is another gauge of confidence that Anaphylm will be approved. What do MSLs do Who are they [--]. MSLs are medical professionals who may be doctors pharmacists physicians assistants (PAs) Nurse practitioners (NPs) and more. [--]. MSLs lay the"  
[X Link](https://x.com/BIOTECHSCANNER/status/1998782583681757196)  2025-12-10T15:51Z [----] followers, [----] engagements


"There is one disease that I root for new treatments every day its Alzheimers disease. There is one disease that I wont invest in its Alzheimers disease. Like MASH its been a graveyard for many biotech companies. I wish it the best though. I read a lot about the latest drug research and development and read about another finding on Alzheimers disease last night Its about the industrial chemical TCE that has been linked with the disease. Fascinating"  
[X Link](https://x.com/BIOTECHSCANNER/status/1999863958438621213)  2025-12-13T15:28Z [----] followers, [---] engagements


"@Mikoppoiu Made 90% on NKLR. You must have entered late. Called AQST at $2.80. Went over $7.50. You must be late too"  
[X Link](https://x.com/BIOTECHSCANNER/status/2009675395168370745)  2026-01-09T17:15Z [----] followers, [---] engagements


"$AQST - Opportunity on a red day for investors who want to add to their portfolio. This will be [--] of the most exciting biotech in 2025"  
[X Link](https://x.com/BIOTECHSCANNER/status/1859691148601852175)  2024-11-21T20:11Z [----] followers, [----] engagements


"$AQST - Not looking for the moon or a rocket. Just looking for an investment opportunity into a solid biotech company with a transformative product that NO PRODUCT from the present or future can match with its DURABILITY EASE OF USE EASY TO CARRY and WORKS FAST. Anaphylm is the holy grail of epinephrine treatment. The first oral needle free non-device treatment on the market soon if approved by the FDA. It will happen. Im 7-0 with PDUFA predictions. Not gonna miss this one 🐉. Its going to be the most rewarding investment of my life and hopefully yours too. Heres to my beloved 🐉family. I"  
[X Link](https://x.com/BIOTECHSCANNER/status/1889720563339514308)  2025-02-12T16:57Z [----] followers, [----] engagements


"$AQST The global epinephrinemarket size is calculated at $3.37 billion in [----] and is expected to reach around $6.93 billion by [----] growing at a CAGR of 8.34% for the forecasted period. The true market size is MUCH MUCH LARGER. Why In a nationwide patient survey by Wood 52% of patients who had previously experienced anaphylaxis had never received an epinephrine auto-injector prescription and 60% of respondents did not have an epinephrine auto-injector currently available. Whats that mean It means doctors are not giving prescription to patients who needed it Worse yet most people (60%) dont"  
[X Link](https://x.com/BIOTECHSCANNER/status/1902823247629939045)  2025-03-20T20:43Z [----] followers, [----] engagements


"$AQST - Aquestive Therapeutics could have easily pursued urticaria indication with Anaphylm as well but CEO Dan Barber knew the market is not great and demand is low. Also there are too many already in this space. ARS Pharmaceuticals ($SPRY) decided to take on the challenge and its going to be a challenge already. Dan Barber made a very wise decision here. AQST [---] for alopecia areata has a much larger market and very few players are in the space currently. https://twitter.com/i/web/status/1913713684171391410 https://twitter.com/i/web/status/1913713684171391410"  
[X Link](https://x.com/BIOTECHSCANNER/status/1913713684171391410)  2025-04-19T21:57Z [----] followers, [----] engagements


"Thats correct. Viatris the company behind EpiPen submitted a citizen petition to the FDA asking that ARS Pharmaceuticals conduct more pharmacokinetic/pharmacodynamic (PK/PD) studies before Neffy could be approved. And it worked because ARS Pharma didnt proactively conducting the repeat dose trial. $AQST did the OASIS trial that is much more thorough than what the FDA needed but the idea of the trial came from the FDA and management. Results were amazing. https://twitter.com/i/web/status/1972084396531302407 https://twitter.com/i/web/status/1972084396531302407"  
[X Link](https://x.com/BIOTECHSCANNER/status/1972084396531302407)  2025-09-27T23:42Z [----] followers, [---] engagements


"@benjamminvr @US_FDA Yes many people have them but dont carry. With Anaphylm many more people will carry. This will have a community effect like vaccination. The FDA knows what a game changer Anaphylm is. They will work with the company to get it to the patients"  
[X Link](https://x.com/BIOTECHSCANNER/status/2009746783048532439)  2026-01-09T21:59Z [----] followers, [---] engagements


"Then why did he not include $SPRY situation and what ultimately happened after the CRL He purposefully ignored this and sows more negativity. Wouldnt he be saying these things if he still owns shares We know the answer to that dont we Bullish posts. Sells for profits. Negative posts. Load on dips. Rinse and repeat. I have seen this many times. This is a classic example of manipulation. https://twitter.com/i/web/status/2010030091258978648 https://twitter.com/i/web/status/2010030091258978648"  
[X Link](https://x.com/BIOTECHSCANNER/status/2010030091258978648)  2026-01-10T16:44Z [----] followers, [---] engagements


"@Shassan_12 @Dansfera Why didnt he bring up what happened in the $SPRY case He has no position and predicting the sp would drop to $2. If he was balanced he should talk about what may happen after. He even mentioned that he would short the stock. Hmmm he is not a short Please man"  
[X Link](https://x.com/BIOTECHSCANNER/status/2010033056523194670)  2026-01-10T16:56Z [----] followers, [---] engagements


"$IOVA - You all know they have a monopoly on this approval right 🤑🤑🤑 EU Canada Australia next"  
[X Link](https://x.com/BIOTECHSCANNER/status/1758682233689280749)  2024-02-17T02:38Z [----] followers, [----] engagements

Limited data mode. Full metrics available with subscription: lunarcrush.com/pricing